Next Article in Journal
Identifying Cancer Driver Genes Using Replication-Incompetent Retroviral Vectors
Next Article in Special Issue
A Comparison of Singlet Oxygen Explicit Dosimetry (SOED) and Singlet Oxygen Luminescence Dosimetry (SOLD) for Photofrin-Mediated Photodynamic Therapy
Previous Article in Journal
The Role of TAM Family Receptors in Immune Cell Function: Implications for Cancer Therapy
Previous Article in Special Issue
Modulation of the Anti-Tumor Efficacy of Photodynamic Therapy by Nitric Oxide
Article Menu

Export Article

Open AccessReview
Cancers 2016, 8(10), 98; doi:10.3390/cancers8100098

Photodynamic Therapy and Non-Melanoma Skin Cancer

Dermatology Centre, Salford Royal NHS Foundation Trust, Manchester Academic Health Science Centre, University of Manchester, Manchester M6 8HD, UK
*
Author to whom correspondence should be addressed.
Academic Editor: Michael R. Hamblin
Received: 11 July 2016 / Revised: 15 October 2016 / Accepted: 18 October 2016 / Published: 22 October 2016
(This article belongs to the Special Issue Photodynamic Cancer Therapy)
View Full-Text   |   Download PDF [583 KB, uploaded 22 October 2016]   |  

Abstract

Non-melanoma skin cancer (NMSC) is the most common malignancy among the Caucasian population. Photodynamic therapy (PDT) is gaining popularity for the treatment of basal cell carcinoma (BCC), Bowen’s disease (BD) and actinic keratosis (AK). A topical or systemic exogenous photosensitiser, results in selective uptake by malignant cells. Protoporphyrin IX (PpIX) is produced then activated by the introduction of a light source. Daylight-mediated MAL (methyl aminolaevulinate) PDT for AKs has the advantage of decreased pain and better patient tolerance. PDT is an effective treatment for superficial BCC, BD and both individual and field treatment of AKs. Excellent cosmesis can be achieved with high patient satisfaction. Variable results have been reported for nodular BCC, with improved outcomes following pretreatment and repeated PDT cycles. The more aggressive basisquamous, morphoeic infiltrating subtypes of BCC and invasive squamous cell carcinoma (SCC) are not suitable for PDT. Prevention of “field cancerization” in organ transplant recipients on long-term immunosuppression and patients with Gorlin syndrome (naevoid basal cell carcinoma syndrome) is a promising development. The optimisation of PDT techniques with improved photosensitiser delivery to target tissues, new generation photosensitisers and novel light sources may expand the future role of PDT in NMSC management. View Full-Text
Keywords: photodynamic therapy; non-melanoma skin cancer; basal cell carcinoma; actinic keratosis; field cancerization; organ transplant recipients; Gorlin syndrome photodynamic therapy; non-melanoma skin cancer; basal cell carcinoma; actinic keratosis; field cancerization; organ transplant recipients; Gorlin syndrome
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Griffin, L.L.; Lear, J.T. Photodynamic Therapy and Non-Melanoma Skin Cancer. Cancers 2016, 8, 98.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Cancers EISSN 2072-6694 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top